array:5 [
  "content-type" => array:1 [
    0 => "text/html; charset=UTF-8"
  ]
  "cache-control" => array:1 [
    0 => "no-cache, private"
  ]
  "date" => array:1 [
    0 => "Sun, 24 Nov 2024 01:03:54 GMT"
  ]
  "set-cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6InVOQTVmVEIrQ3dhc1dxRFBCWnZEbEE9PSIsInZhbHVlIjoidzd0anlUS3ZpenFsL3NaUXpIRUxWUEdlTFJOVlZZMHlxSUk0UnRWcU5jNkhIR05pOVFFTFNBbU0vQmZGQzl0azV1VVlzVldPNlFOZ1ZkRnNaV2ZvOW9tQkRwdERhZlhJeGtGWVpMejdBTGFvUC8wL3pDZWxjR1lqUkxKaFFmMDAiLCJtYWMiOiIyMmUyNmZmYjY0YjcwOWI1ZWI0YTg4MDJhMzcyMmQzOWEwY2YzYTVjMjE2NDQ2ZThmYjg2ZDdkZTgzMmNhOTUxIiwidGFnIjoiIn0%3D; expires=Mon, 24 Nov 2025 01:03:54 GMT; Max-Age=31536000; path=/; secure; samesite=lax"
    1 => "republica_session=eyJpdiI6InRXaThSY2czM3ZPamZKZ2dMcGh2K3c9PSIsInZhbHVlIjoiWHFRNDA4YUFTaVNuT3c5enZ6MVdidUN0cHhHNEthcGdiMkpFK0xYV3lXRzFua2tRRVFVY2VEa29wRXd1WWNJbnhVMmJEbHltdndxZmJSWk9naXcyR3EyOGNKOUNoeTVwWlZFTldvcW0zbnlGd3BKeGhTNHgvMHRkZndMZGdJcFYiLCJtYWMiOiJkMTIzMWFmNGJjYjRiOTk5M2JjNTAxOTBlOWM0OWM1NTgzNGQ1YjYxYzkyYmI4YzgwNDQzNWZkNDg3OWJjNDI4IiwidGFnIjoiIn0%3D; expires=Mon, 24 Nov 2025 01:03:54 GMT; Max-Age=31536000; path=/; secure; httponly; samesite=lax"
  ]
  "Set-Cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6InVOQTVmVEIrQ3dhc1dxRFBCWnZEbEE9PSIsInZhbHVlIjoidzd0anlUS3ZpenFsL3NaUXpIRUxWUEdlTFJOVlZZMHlxSUk0UnRWcU5jNkhIR05pOVFFTFNBbU0vQmZGQzl0azV1VVlzVldPNlFOZ1ZkRnNaV2ZvOW9tQkRwdERhZlhJeGtGWVpMejdBTGFvUC8wL3pDZWxjR1lqUkxKaFFmMDAiLCJtYWMiOiIyMmUyNmZmYjY0YjcwOWI1ZWI0YTg4MDJhMzcyMmQzOWEwY2YzYTVjMjE2NDQ2ZThmYjg2ZDdkZTgzMmNhOTUxIiwidGFnIjoiIn0%3D; expires=Mon, 24-Nov-2025 01:03:54 GMT; path=/; secure"
    1 => "republica_session=eyJpdiI6InRXaThSY2czM3ZPamZKZ2dMcGh2K3c9PSIsInZhbHVlIjoiWHFRNDA4YUFTaVNuT3c5enZ6MVdidUN0cHhHNEthcGdiMkpFK0xYV3lXRzFua2tRRVFVY2VEa29wRXd1WWNJbnhVMmJEbHltdndxZmJSWk9naXcyR3EyOGNKOUNoeTVwWlZFTldvcW0zbnlGd3BKeGhTNHgvMHRkZndMZGdJcFYiLCJtYWMiOiJkMTIzMWFmNGJjYjRiOTk5M2JjNTAxOTBlOWM0OWM1NTgzNGQ1YjYxYzkyYmI4YzgwNDQzNWZkNDg3OWJjNDI4IiwidGFnIjoiIn0%3D; expires=Mon, 24-Nov-2025 01:03:54 GMT; path=/; secure; httponly"
  ]
]
AstraZeneca suspends leading COVID-19 vaccine trials after a participant's illness

AstraZeneca suspends leading COVID-19 vaccine trials after a participant's illness

Create an account, or log in
